Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

25.66 +0.80 (+3.22%)
Streaming Delayed Price Updated: 10:28 AM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
3 Vaccine Stocks to Buy as the FDA Cracks Down on New Variants
After the FDA's authorization of a Covid19 booster shot, you may want to consider adding these vaccine stocks to your portfolio. 
Via InvestorPlace
Exposures Product Safety
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
What's Going On With Moderna Stock Monday?
Moderna said its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, met its primary endpoints. 
Via Benzinga
Exposures COVID-19
Nike, Merck, General Motors, And More: CNBC's 'Final Trades'
Liz Young of SoFi recommends Energy Select Sector SPDR Fund as her final trade on CNBC's Halftime Report. Jim Lebenthal of Cerity Partners picks General Motors, while Jason Snipe of Odyssey Capital... 
Via Benzinga
Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
Via ACCESSWIRE
If You Invested $100 In This Stock 5 Years Ago, You Would Have $800 Today
Via Benzinga
Breaking Down Moderna: 7 Analysts Share Their Views
Via Benzinga
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
If approved, this would be the first combination vaccine based on mRNA technology to hit the market. 
Via Investor's Business Daily
Exposures COVID-19
Why Moderna Stock Is a No-Brainer Buy Right Now
This messenger-RNA pioneer should be able to keep its rebound going. 
Via The Motley Fool
Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
Via ACCESSWIRE
3 Reasons to Buy Moderna Stock
The biotech hasn't said its last word. 
Via The Motley Fool
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1. 
Via Benzinga
Exposures COVID-19 Product Safety
5 Stocks Propelling S&P 500 To 25th Record High
While most of the stocks have performed well, here are five of them that led the way higher in yesterday's trading session. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
Via AB Newswire
First Human Death From Bird Flu Strain Puts Vaccine Stocks Back On The Map
Moderna shares are up almost 29% this month; CureVac is up 72% in the past month; and Novavax spiked 317% in the past month. 
Via Benzinga
Novavax Stock’s Recent Surge and Future Potential
Novavax's future hinges on its ability to translate recent stock market momentum into sustained financial performance. 
Via MarketBeat
Topics Economy
Exposures COVID-19 Product Safety Supply Chain
FDA Selects Moderna's Rare Disease Candidate For Accelerated Development Program
Moderna's mRNA-370 has been selected for the FDA's START program to accelerate rare disease therapeutics, targeting a 2024 pivotal study. 
Via Benzinga
Exposures Product Safety
Is a Giant Short Squeeze Brewing in Novavax (NVAX) Stock?
Novavax will be ready for the new Covid-19 JN.1 variants in September, but NVAX stock is also undergoing a short squeeze. 
Via InvestorPlace
Exposures COVID-19
Novavax, With A 369% Gain, Tears Ahead Again On Key FDA Move
Novavax also said it's planning to launch a JN.1-focused Covid booster shot this fall. 
Via Investor's Business Daily
Exposures COVID-19 Product Safety
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
Via AB Newswire
Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
Via ACCESSWIRE
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential
If you have the patience and the ability to take a little risk, consider these three biotech stocks to buy since they can really pay off. 
Via InvestorPlace
Why Is Novavax (NVAX) Stock Up 20% Today?
Novavax continues to march higher in its recovery efforts, with its latest vaccine announcement lifting NVAX stock. 
Via InvestorPlace
S&P 500, Nasdaq 100 Jointly Hit All-Time Highs, Nvidia Overtakes Apple As Second Most Valuable US Company
The S&P 500 and Nasdaq 100 indices closed at record highs due to investor confidence in AI-driven tech sector growth. Magnificent Seven worth $15T. 
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Novavax Stock?
Novavax, Inc. shares are trading higher Wednesday, and the stock is up by more than 300% over the past month. Here's a look at what's going on. 
Via Benzinga
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial.  On Monday, Moderna (NASDAQ: MRNA) and Merck & Co... 
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate 
Via InvestorPlace
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
Moderna and Merck's Phase 2b study results for mRNA-4157 combined with Keytruda, showing improvements in recurrence-free and distant metastasis-free survival for high-risk melanoma patients. Phase 3... 
Via Benzinga
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage
Via ACCESSWIRE
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.